For virologically suppressed adult patients with HIV-1. See Full Indication.

JULUCA | Risks & Side Effects


  • Do not use JULUCA in patients with previous hypersensitivity reaction to dolutegravir or rilpivirine
  • Do not use JULUCA in patients receiving dofetilide, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, systemic dexamethasone (>1 dose), St John's wort, and proton pump inhibitors (eg, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole)

Warnings and precautions

Skin and Hypersensitivity Reactions:

  • Hypersensitivity reactions have been reported with dolutegravir and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury
  • Severe skin and hypersensitivity reactions have been reported during postmarketing experience, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), with rilpivirine-containing regimens and have been accompanied by fever and/or organ dysfunctions, including elevations in hepatic serum biochemistries
  • Discontinue JULUCA immediately if signs or symptoms of severe skin or hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated


  • Hepatic adverse events have been reported, including cases of hepatic toxicity (elevated serum liver biochemistries, hepatitis, and acute liver failure) in patients receiving a dolutegravir-containing regimen without pre-existing hepatic disease or other identifiable risk factors
  • Patients with underlying hepatitis B or C or marked elevations in transaminases prior to treatment may be at increased risk for worsening or development of transaminase elevations with the use of JULUCA. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, particularly in the setting where anti-hepatitis therapy was withdrawn
  • Monitoring for hepatotoxicity is recommended

Embryo-Fetal Toxicity:

  • Assess the risks and benefits of JULUCA and discuss with the patient to determine if an alternative treatment should be considered at the time of conception through the first trimester of pregnancy due to the risk of neural tube defects
  • Pregnancy testing is recommended before use of JULUCA. Individuals of childbearing potential should be counseled on the consistent use of effective contraception

Depressive Disorders:

  • Depressive disorders (including depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, and suicidal ideation) have been reported with rilpivirine
  • Promptly evaluate patients with severe depressive symptoms

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions:

  • The concomitant use of JULUCA and other drugs may result in known or potentially significant drug interactions (see Contraindications and Drug Interactions)
  • Rilpivirine doses 3 and 12 times higher than the recommended dose can prolong the QTc interval. Consider alternatives to JULUCA when coadministered with a drug with a known risk of Torsade de Pointes. Consider the potential for drug interactions prior to and during therapy with JULUCA and monitor for adverse reactions

Adverse Reactions and Rates of Discontinuation Due to Adverse Events Through Week 1481,2*

Adverse Reactions and Rates of Discontinuation Due to Adverse Events Through Week 100
Adverse Reactions and Rates of Discontinuation Due to Adverse Events Through Week 100

*SWORD 1 & 2 (pooled data).
Of the people who took JULUCA from Week 1 and left the study due to adverse events, the most common type of adverse event leading to discontinuation was psychiatric disorders (3%).

AE=adverse event; ART=antiretroviral therapy.


  1. van Wyk J, Orkin C, Rubio R, et al. Durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from SWORD-1 and SWORD-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;85:325-330. doi: 10.1097/QAI.0000000000002449
  2. Data on file, ViiV Healthcare.

You may also be interested in

Clinical Trials


Read more »


Read more »
Educational Resources


Read more »